Building, Embedding & Optimizing Market Access Capabilities – From Strategy to Execution

Symposium, ISPOR, Dublin, Ireland – 4th November 2013
Symposium Objectives

1. To explore reasons why & consequences of lack of full integration of market access into Pharma company development & commercialisation processes

2. To explore via case studies & discuss ideas for improving methods to embed market access into Pharma company development & commercialisation processes
# Symposium Agenda

<table>
<thead>
<tr>
<th>Session</th>
<th>speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.30am Objectives &amp; Introduction</td>
<td><strong>Colin Wight</strong>, CEO GalbraithWight</td>
</tr>
</tbody>
</table>
| Case Study 1: **Global R&D Clinical Development Process**  
- Building & Embedding Market Access Requirements into R&D | **Jackie Briggs**, Principal Consultant, GalbraithWight |
| Case Study 2: **European Regional Market Access team**  
- Building Market Access Processes & Capabilities across the team | **Tanea Neville**, Principal Consultant, GalbraithWight |
| Case Study 3: **New Products Planning at Country Level**  
- Embedding Market Access into NPP and Launch Excellence | **Janet Waters**, Principal Consultant, GalbraithWight |
| Case Study 4: **Automating Market Access planning for Launch**  
- Optimising Launch Excellence planning in a web-based tool | **Debbie Thompson**, Principal Consultant, GalbraithWight |
| Case Study 5: **Strategic Brand Planning**  
- Embedding Market Access into Strategic Brand Planning Process | **Mark Boyden**, Principal Consultant, GalbraithWight |
| Case Study 6: **Building a Market Access Centric internal organisation**  
- Building, Embedding & Communicating a market-access based philosophy across an international organisation | **Emma Rawlins**, Principal Consultant, GalbraithWight |
| Panel Discussion | **Keith Tolley**, Economic Assessor, Scottish Medicines Consortium  
**Colin Wight**, CEO GalbraithWight |
| Conclusions |  |
| 8.30am Close |  |
Pharma industry now takes Market Access seriously

We actively **measure** it

![Bar chart showing average time from EU market authorisation to accessibility date for medicines with first EU marketing authorisation in the period 2007-09](chart.png)

**Source:** Patients WAIT Indicator 2010, EFPIA

We talk & **listen to Payer** customers

“Perception of value drives the willingness to pay, and those perceptions vary from country to country,” “We need to do a much better job communicating value to payers”  
*Roger Woodrow, Vice President, Specialty Business Unit, Pfizer September 2011*

We’ve created **Market Access teams** & hired HEOR experts – in house & agencies

There are good examples of **best practice**
But...Pharma performance in launching new products is declining

According to data provider IMS, commercial performance of Pharma launches is declining.

OHE concluded that overall, cumulative clinical success rates appear to have decreased over time.
The financial risk not launching brands successfully is huge – through delayed access

Impact of delayed access on industry profitability

- Less time available for commercialisation before patent expiry
- Profit lost from peak sales due to delay in access at launch
The financial risk not launching brands successfully is huge – through poor launch panning & implementation

Impact of launch effectiveness on industry profitability

Sales

Significantly reduced Area under the curve

Less effective launch

Launch

profit lost from peak sales due to less effective launch

Time
Industry needs to do a much better job in the debate around measuring & rewarding ‘value’ for innovation

“The Committee acknowledged that few advances had been made in the treatment of advanced melanoma in recent years and ipilimumab could be considered a significant innovation for a disease with a high unmet clinical need”

NICE FAD November 2012
Value delivered by the same medicine varies by disease

- Bevacizumab in combination with a taxane for the first-line treatment of **metastatic breast cancer** - ICER for bevacizumab plus paclitaxel versus weekly paclitaxel was between £110,000 and £259,000 per QALY gained.

- Bevacizumab in combination with oxaliplatin-containing regimens as a second-line treatment for **metastatic colorectal cancer** the ICER was £103,000 per QALY gained.

- Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of **advanced ovarian cancer** gave a range of ICERs from £128,000 to £161,000 per QALY gained.

- Etanercept for **active polyarticular-course juvenile idiopathic arthritis** whose condition has not responded adequately to, or who have proved intolerant of, methotrexate the ICER is in the region of £15–30,000 per QALY.

- Etanercept for **first-line treatment for early RA**, the estimated ICER with methotrexate is £78,100 per QALY.

- Etanercept in **adults with active psoriatic arthritis**, the ICER was £12,480 per QALY gained when compared with best supportive care.

Source: www.nice.org.uk
The value of innovative medicines is delivered over decades, with the majority of benefit delivered by generic use post patent expiry

“The fact that such a large proportion of the social surplus being appropriated by others than the innovator highlights the relevance of a societal perspective in economic evaluation. It may also make a case for considering looking a dynamic cost–effectiveness when assessing the introduction of new therapies.”

Fig. 1 The total cost of simvastatin prescriptions and the number of patients treated in Sweden 1987–2008. Source: National board of Health and Welfare [21], sales data from MSD Sweden AB and Apoteksbolaget AB (data on file)

There are some perverse internal incentives around market access

Industry has tended to build functional or therapeutic silos in Pharma, & market access is the latest version.

There is sometimes an apparent complicity between many Marketers that market access is ‘too complicated’ with HEOR technical experts happy to agree with them to protect their own value to the company.

The result? No joined up thinking, planning & action across the brand teams at global, region & country level – so no overall company capability in market access
All functions need to closely align to work together to effectively satisfy the requirements of all Market Access stakeholders.

No functional group on their own has the answer!

Market Access needs to be a company-wide capability.
Great! Another new corporate initiative!

Many initiatives are started as **stand alone** projects so they do not get ‘too complicated’ – in particular initiatives which are ‘Big Consultancy led’ tend to be **designed as stand alone** deliverables

What companies & teams really need is **integrated processes** which promote **joined up thinking & cross-functional working**

Market Access, New Product Planning, Launch Excellence & Brand Planning are all elements of a **continuum**
Case Study 1:
Building & Embedding Market Access Requirements into the global R&D Clinical Development Process

Jackie Briggs – Principal Consultant, GalbraithWight
What was the challenge?

The client:
- Global Market Access Director of a medium-sized Pharma

The challenge:
- Market Access not yet fully embraced, particularly within R&D where focus on requirements for first Marketing Authorisation Approval
- Company ethos entrepreneurial, not limited by structures and processes, allowing people freedom to make their own decisions
- A need to demonstrate to executive team causes of Market Access issues as well as drivers of Market Access so they could address them in a more systematic way
- Possible lack of training and understanding about Market Access in global brand teams, no formal structure or process for new products planning & inconsistency in interpretation for terms ‘Target Product Profile’ and ‘Minimal Acceptable Product Profile’ between teams
Methods & Outcomes

• Conducted interviews with Senior Management team - *What did Market Access mean to them? - How should it be addressed?*

• Identified key findings & conducted Gap Analysis to identify how, where, when and what MA tools and processes needed

• Sought senior management buy-in to proposals

• Conducted interactive workshops with global teams to share key findings, train and seek feedback on proposed educational tools and processes

• Finalised a first ever set of MA tools and processes for the company to address MA needs across the product lifecycle – from project initiation to patent expiry
Results

An agreed new process for what Market Access activities are required when, embedded into the organisation’s existing process for R&D Gates and Milestones, rolled out to all teams across the organisation

- Full senior management support for the need for MA to be integral to all stages of product development
- Market Access tools bringing consistency in timing, format and standard of all MA activities, assessments & deliverables

Market Access at the core of the organisation in a way that was practical and straightforward for the company to adopt

‘We have to elevate the awareness of this company to what market access means, from the standpoint of the different players – manufacturing, R&D, QA, commercial etc. They have to understand that there is one place where everything’s got to come together and it’s called Market Access.’

Company President
Case Study 2
Building Market Access Processes & Capabilities for a new Market Access European Regional team

Tanea Neville – Principal Consultant GalbraithWight
What was the challenge?

The client:
• Director of Market Access at the European Headquarters of a medium-sized fast growing Pharma company

The challenge:
• To really understand what is needed to achieve and maintain access and to determine what is required of an organisation to deliver Market Access success - across pipeline, launch and in-line brands
• To be understood in terms of:-
  – Processes, frameworks and tools
  – Competencies and skill sets required
  – Organisational Design
  – ‘Ways of Working’ across functions at regional headquarters and between European HQ and countries
Methods & Outcomes

Insights from Research & Analysis
• Large number of in-depth internal stakeholder interviews across functions at EHQ
• Internal Interviews across a large number of lead market countries
• External Environment reporting
• Global Company Benchmarking assessment
• Internal pipeline and portfolio analysis

Engagement Approach
• Interactive workshops with project specific task force representing a wide range of departments and functions
• Formation of and communication with Market Access Leadership team and Market Access Council (of nations)
• Development of an external network of experts for on-going consultation with across Europe
What was Delivered

- Market Access Planning Timeline
  - A structured process with milestones & deliverables to achieve and maintain access
  - Spanning pipeline, launch and in-line brands
  - Dovetailing with Launch Excellence process

- Strategic & Tactical market Access Plan
  - Comprehensive objectives and priorities
  - Linking regional headquarter planning to country affiliate planning
What was Delivered

• Market Access Activity Templates
  – Activity by function with objectives, roles & responsibilities and quality standards

• 10 Step Competency Framework
  – Linked to a training curriculum to develop priority skill sets

• Recommendations for Market Access resourcing aligned to current and near future organisational demands
Results

A mind-set shift in understanding the complex requirements to achieve & maintain successful Market Access for pipeline, launch brands and in-line brands

• Clearer roles & responsibilities against defined activities across departments with accountability and quality standards built in

• Recognition that greater inputs from commercial development & marketing are required earlier in an asset’s development process

• A structured process with milestones & deliverables to achieve and maintain access

• Clarity around regional headquarter requirements & in-country market access challenges; leading to redeployment of & realignment of resource to meet access demands

• Market Access tools & templates that ‘bring to life’ and prioritise the timing, format and standard of all MA activities, assessments & deliverables

• Insight into the skills required and existing levels of knowledge and competencies across several functions of the organisation

“...key measures to demonstrate value and build the Value Proposition need to be included in early clinical studies”

Regional Head of Marketing

Successful Market Access cannot be the responsibility of a single department or function.......“everyone should own and be accountable”

Oncology Business Unit Director
Case Study 3
Embedding Market Access within New Products Planning & Launch Excellence Process at Country level

Janet Waters – Principal Consultant, GalbraithWight
What was the challenge?

The client:
- New Products Planning Manager in a country affiliate of large Pharma

The challenge:
- Suboptimal Market Access planning likely to compromise launch performance
- No process to enable early enough or rigorous enough engagement to influence
  - Target Reimbursable Product Profile
  - comparators and outcomes to be included in Ph III
  - Potentially unready for timely implementation of MA activity at country level
- Country level resources are focussed on achieving this year/next year plan.
  - Limited country-level resource allocated for pipeline products
- New Products function confined to being reactive to Global/Regional requests (e.g. forecasts) rather than enabling an informed country level evaluation
- Need to engage executive team to create change
Methods & Outcomes

- Partnered with the New Products Manager

- Identified gaps in current ways of working

Examples of Allocated Roles

Client
- Internal communications
- Interviews
- Liaison with executive team
- Cross departmental consultation
- Championing the project

GalbraithWight
- Managing workshop
- Analysis
- Process development
- Tools development
- Mentoring initial application
- Documentation
Methods & Outcomes

- Partnered with the New Products Manager

- Identified gaps in current ways of working,

- Deduced and mapped on a timeline the critical inputs and actions
  - impact on global plans as well as local

Example of Guidance for actions by Timepoint

- **During Ph II**
  - Prepare local evaluation

- **End of Ph II**
  - Give well-informed input to Global
  - Market Access needs, comparators, trial centers

- **Start of Ph III**
  - Assess gaps between Global plan and local requirements
  - Propose local action plan
Methods & Outcomes

- Partnered with the New Products Manager

- Identified gaps in current ways of working,
  - Deduced and mapped on a timeline the critical inputs and actions
    - impact on global plans as well as local

- Created New Product Planning Process aligned with global development stages
Methods & Outcomes

- Developed commercial evaluation process for pipeline assets,
  - Categorisation according to country priorities
  - Justification for level of investment at country level

- Proposed governance structure
  - Executive team oversight
  - Accessing approval & sponsorship of planning resources
Methods & Outcomes

- Included senior management at each stage
  - draft proposals were anticipated

- Bridged from New Products Planning to Launch planning process
  - appropriate timescale for Market Access activities
  - joined-up process to transition from New Products to Brand Team
## Results

| Robust Commercial Evaluation | Country affiliate enabled to make informed evaluations of pipeline assets for the country market |
| Process Aligned with Global Development Stages | Informed discussion with Global about Market Access opportunities, based on a robust case for country needs – |
| Governance Structure | Enhanced understanding of country inputs to Global & time frame of influence |
| | Greater leverage for country-appropriate health economic and outcome measures to be collected during Ph III |
| Joined up with Launch Excellence | Highly Informed executive team, better prepared for future portfolio impacts and resourcing requirements |
| | Improved decision-making about appropriate time frame to hand over to brand team |
| | Market Access planning and execution as a continuum |
Results

Early results:

- Successful advocacy
- Additional comparator included in Phase III trials
- Appropriate for demonstrated market access opportunities
Case Study 4
Optimising Launch Excellence Planning with Market Access embedded in a web-based tool

Debbie Thompson – Principal Consultant, GalbraithWight
Launch Excellence Planning – What was the challenge?

1. Maximise the potential of future product launches
2. Strengthen competitive advantage
3. Establish a consistent framework
4. Develop a pragmatic approach

“We are aiming for a new standard and consistently applied approach to Launch Excellence”
Insights uncovered summed up in 4 areas

The need for One Truth

Timing – Start Earlier

Teamwork

Touchpoints
## Methods & Outcomes

### Requirements for Launch Excellence

<table>
<thead>
<tr>
<th>Requirement</th>
<th>Addressed</th>
</tr>
</thead>
<tbody>
<tr>
<td>All preparatory steps to be taken in a timely fashion.</td>
<td>Looked at how the process could be automated</td>
</tr>
<tr>
<td>Commercial evaluation linked to an assessment system to inform strategic decision making</td>
<td>Developed web-based tool to allow people to:</td>
</tr>
<tr>
<td>Set ‘review’ points through the pre launch process</td>
<td>1. Know what they need to do and when</td>
</tr>
<tr>
<td></td>
<td>2. Incorporate inter-dependencies</td>
</tr>
<tr>
<td></td>
<td>3. See progress at a glance</td>
</tr>
</tbody>
</table>
1. Lets people know what they need to do and when...
2. Allows automation of interdependencies between functions
3. Lets people see an overview of how things are going
Outcome

The client has moved their mind-set from:
“Preparing for Launch” to “Being Brand Ready”

…from “Being Prepared” to being “Ahead of the Game” with everything in place and everyone clear about their responsibilities…

…and an automated tool with market access embedded can help to make it happen

Thank you
Case Study 5
Embedding Market Access into Strategic Brand Planning Process

Mark Boyden – Principal Consultant, GalbraithWight
What was the challenge?

**The client:**
- European lead for Market Access capability

**The challenge:**
- Refusals or restrictions on reimbursement
- Sub optimal formulary acceptance
- Weak support at a Regional or local budget holding level resulting in sub optimal brand use even within the patients authorised in formulary guidelines
- Weak use in the private Healthcare system channel
  - Slow uptake of new brands at launch

**Why?**

- Still operating with the old ‘Blockbuster’ model, focused almost exclusively on clinical stakeholders with little or no understanding of payers and policy makers and impact on achieving Market Access
Methods & Outcomes

1. Re-engineered brand planning process to embed MA requirements throughout

2. Ensured common understanding of the nature, scope and requirements for MA

3. Ensured Regional brand plans provided support and guidance to country teams in fully addressing Market Access at local level

4. Ensured full internal stakeholder engagement - vertically and horizontally

5. Mediated delivery through a multi channel programme
MA LANDSCAPE ANALYSIS: unmet need; SOC; payer drivers; incremental value delivered by competitors today and future.
• Where are the opportunities as well as the barriers?

FUNDS FLOW analysis at target leverage points: how is the money spent today?; who controls it?: DRGs

MARKET ACCESS STRATEGY for each Life Cycle Milestone:
• Unmet need
• SOC
• Position in treatment algorithm
• Source of incremental clinical benefit
• Basis for economic justification
• Pricing strategy: level and approach
• Target leverage points
Results

BEHAVIOURS:

• Everyone now speaking the same language around brand planning and market access leading to:
  – greater team understanding of the ‘real issues’, quickly! (Unmet need, SoC, ICEB)
  – more alignment in cross functional development of options to resolve the issues
  – improved decision making to identify the best option

• Strategy first, without jumping straight into tactics!

• More active payer engagement at National, Regional and Local level

BUSINESS OUTCOMES:

• Improved rates of brand uptake through faster and wider Market Access through:
  – Faster times for reimbursement approval
  – Increased payer support at local level driving improved formulary placement
Case Study 6
Building, Embedding & Communicating a market-access based philosophy across an international organisation

Emma Rawlins – Principal Consultant, GalbraithWight
What was the challenge?

The Client
• European Headquarters of a large Pharmaceutical Company

The challenge
• How can we ensure that everyone in the commercial organisation considers Market Access to be a part of their role?

• How can we ensure that all of the market access requirements are met without adding significant additional market access resource?

• Market access is not just about launch products – but should be considered as part of life cycle management for all the products in our portfolio
Methods & Outcomes

• **Woven into all aspects of European Marketing Excellence Programme**
  – Training Curriculum – including specific market access course
  – Strategic Brand Planning and link to tactical budget allocation
  – E-book to support brand planning
  – Launch Preparation
  – Communications plan
  – Internal website
  – Pan-European awards
  – Strong branding of the programme

• **Bringing it to life**
  – Presentation and discussion session with ‘live’ payers
  – Video interviews with national and regional payers
  – Debate about the responsibility for market access
  – Range of tools and approaches
    • E.g. Forces and Needs analysis
### Customer Type – Hospital Budget Holder

<table>
<thead>
<tr>
<th>Forces</th>
<th>Needs</th>
<th>Implication for Value Proposition and Messaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>Favorable public opinion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pressure to make quick decisions. Patients and physicians don’t want to wait</td>
<td></td>
<td></td>
</tr>
<tr>
<td>To make the best use of the budget they have</td>
<td></td>
<td></td>
</tr>
<tr>
<td>To keep healthcare system functioning - patients and resources moving smoothly</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Keep bureaucracy down (paperwork) for physicians</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Customer Type – Hospital Budget Holder

<table>
<thead>
<tr>
<th>Forces</th>
<th>Needs</th>
<th>Implication for Value Proposition and Messaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>Favorable public opinion</td>
<td>Be able to demonstrate delivering improved Health Outcomes</td>
<td></td>
</tr>
<tr>
<td>Pressure to make quick decisions. Patients and physicians don’t want to wait</td>
<td>Clear, accurate, concise and relevant information for medicines and interventions to enable rapid decision making</td>
<td></td>
</tr>
<tr>
<td>To make the best use of the budget they have</td>
<td>Be able to demonstrate that they have achieved improved health outcomes for the money invested</td>
<td></td>
</tr>
<tr>
<td>To keep healthcare system functioning - patients and resources moving smoothly</td>
<td>Demonstrate / evidence how they have improved efficiency of care pathways / use of HC resources</td>
<td></td>
</tr>
<tr>
<td>Keep bureaucracy down (paperwork) for physicians</td>
<td>Demonstrate delivery of simplified processes for physicians (helping to enable more patient care time)</td>
<td></td>
</tr>
</tbody>
</table>
# Customer Type – Hospital Budget Holder

<table>
<thead>
<tr>
<th>Forces</th>
<th>Needs</th>
<th>Implication for Value Proposition and Messaging</th>
</tr>
</thead>
<tbody>
<tr>
<td>Favorable public opinion</td>
<td>Be able to demonstrate delivering improved Health Outcomes</td>
<td>Include clear and easily shared outcomes data</td>
</tr>
<tr>
<td>Pressure to make quick decisions. Patients and physicians don’t want to wait</td>
<td>Clear, accurate, concise and relevant information for medicines and interventions to enable rapid decision making</td>
<td>Rapid access to key data to meet decision making criteria</td>
</tr>
<tr>
<td>To make the best use of the budget they have</td>
<td>Be able to demonstrate that they have achieved improved health outcomes for the money invested</td>
<td>Show improved health outcomes which meet the customer needs</td>
</tr>
<tr>
<td>To keep healthcare system functioning - patients and resources moving smoothly</td>
<td>Demonstrate / evidence how they have improved efficiency of care pathways / use of HC resources</td>
<td>Resource mapping tool</td>
</tr>
<tr>
<td>Keep bureaucracy down (paperwork) for physicians</td>
<td>Demonstrate delivery of simplified processes for physicians (helping to enable more patient care time)</td>
<td>Simple process maps and possibly tools</td>
</tr>
<tr>
<td>Forces</td>
<td>Needs</td>
<td>Implication for Value Proposition and Messaging</td>
</tr>
<tr>
<td>--------</td>
<td>-------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Favorable public opinion</td>
<td>Be able to demonstrate delivering improved Health Outcomes</td>
<td>Include clear and easily shared outcomes data</td>
</tr>
<tr>
<td>Pressure to make quick decisions. Patients and physicians don’t want to wait</td>
<td>Clear, accurate, concise and relevant information for medicines and interventions to enable rapid decision making</td>
<td>Rapid access to key data to meet decision making criteria</td>
</tr>
<tr>
<td>To make the best use of the budget they have</td>
<td>Be able to demonstrate that they have achieved improved health outcomes for the money invested</td>
<td>Show improved health outcomes which meet the customer needs</td>
</tr>
<tr>
<td>To keep healthcare system functioning - patients and resources moving smoothly</td>
<td>Demonstrate / evidence how they have improved efficiency of care pathways / use of HC resources</td>
<td>Resource mapping tool</td>
</tr>
<tr>
<td>Keep bureaucracy down (paperwork) for physicians</td>
<td>Demonstrate delivery of simplified processes for physicians (helping to enable more patient care time)</td>
<td>Simple process maps and possibly tools</td>
</tr>
</tbody>
</table>
Metrics – what we measure

- **Course Attendance and Evaluations**
  - Courses attended by 66% of all marketers in Europe
  - 230 course delegates – average score = 9.2 out of 10

- **Planned behaviour change**
  - Action plans from over 90% of delegates

- **Actual behaviour change**
  - Market access included in 100% of affiliate and head office brand plans

- **Business Impact**
  - Currently collecting business impact information
Results

Acceptance of responsibility for delivering market access, using current resources, right across the product lifecycle

• Active agreement from all delegates that have engaged with the programme that they share the responsibility for market access – we are seeing BEHAVIOUR CHANGE

• All course delegates submitted an action plan to show what steps they will be putting in place, who will be involved and when it will be completed. People are TAKING RESPONSIBILITY

• All delegates are currently being followed up 6 months later to see how successful they have been in implementing their action plans and what the actual or anticipated impact on the business will be. Measuring BUSINESS IMPACT
Panel Discussion:

Keith Tolley – Economic Assessor, Scottish Medicines Consortium (SMC)
Colin Wight – CEO, GalbraithWight
Summary:

Colin Wight – CEO, GalbraithWight
Summary

1. Patient & healthcare systems are not getting access to innovative life saving or life enhancing medicines quickly enough in some cases because Pharma industry is potentially losing time & money by not fully integrating market access requirements into development & commercialisation processes – depth & breadth

2. Market access needs to be a company-wide capability, across all functions, with leadership from Market Access experts

3. Building market access capability across the organisation is more about hearts & minds - not just processes & templates

4. Market access is a critical component of a wide range of Pharma company development & commercialisation processes and needs to be embedded within;
   - Clinical development from early phase
   - Business development/licensing due diligence
   - New product planning
   - Launch excellence/launch readiness
   - Brand planning
   - Marketing/commercial excellence

5. Some of these processes lend themselves to a level of automation to enable companies to do more with less, and improve communication
Contact information

GalbraithWight Ltd
GalbraithWight House
Chaucer Business Park
Dittons Road
Polegate
East Sussex
BN26 6QH
United Kingdom

Tel: +44 1323 482 208

www.galbraithwight.com

© All content confidential & Copyright of GalbraithWight Ltd.

GLOBAL
Colin Wight
E: c.wight@galbraithwight.com
M: +44 7889 413 075

Mary Skeels
E: m.skeels@galbraithwight.com
M: +44 7799 205 526

Mark Boyden
E: m.boyden@galbraithwight.com
M: +44 7723 098 657

Business School
Trudie Loveridge
E: t.loveridge@galbraithwight.com
M: +44 7788 452339

EUROPE
Kevin Brent
E: k.brent@galbraithwight.com
M: +44 7811 349832

USA
Nicky Hall (NJ)
E: n.hall@galbraithwight.com
M: +1 732 647 6075

Lindi Nicol (CA)
E: l.nicol@galbraithwight.com
M: +1 858 784 1763

Lori Katz (NJ)
E: l.katz@galbraithwight.com
M: +1 609 468 4882

ASIA PACIFIC
Glenda Crawford (Australia)
E: g.crawford@galbraithwight.com
M: +61 408 068 841

Jane Thomas (China)
E: j.thomas@galbraithwight.com
M: (on request)
Building, Embedding & Optimizing Market Access Capabilities
– From Strategy to Execution

Symposium, ISPOR, Dublin, Ireland – 4th November 2013